China’s Henlius carves out $440M T-cell engager deal with Amberstone
Fuente:
FierceBiotech
Fosun Pharma subsidiary Henlius Biotech has signed a $440 million biobucks deal with California-based Amberstone Biosciences to work on T-cell engagers.